12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Company News  |  Deals

Symphogen, Merck KGaA deal

Symphogen granted Merck exclusive, worldwide rights to develop and commercialize cancer product Sym004. Symphogen will receive €20 million ($25.2 million) up front and is eligible for up to €475 million ($597.4 million) in milestones, plus royalties. Sym004 is a combination of two anti-

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >